Q2 2025 Palatin Technologies Inc Earnings Call Transcript
Key Points
- Palatin Technologies Inc (PTN) reported a significant decrease in net cash used in operations, from $10.5 million in the previous year to $4.8 million for the quarter ended December 31, 2024.
- The company achieved a reduction in net loss, reporting a net loss of $2.4 million for the quarter, compared to $7.8 million for the same period in 2023.
- Palatin Technologies Inc (PTN) completed a Phase 2 study on obesity treatment, with topline data expected soon, indicating progress in their research and development efforts.
- The company is actively engaged in discussions with potential partners for out-licensing opportunities, particularly in their ulcerative colitis and diabetic kidney disease programs.
- Palatin Technologies Inc (PTN) has a strategic focus on developing Melanocortin-4 receptor agonists for obesity treatment, a market projected to exceed $100 billion annually.
- Palatin Technologies Inc (PTN) did not record any product sales to pharmacy distributors for the second quarter ended December 31, 2024, following the sale of rights to COSAT Pharmaceuticals.
- The company recorded a fair value adjustment loss of $8.1 million related to warrant liabilities, impacting their financial results.
- Palatin Technologies Inc (PTN) reported a decrease in cash and cash equivalents, with $3.4 million as of December 31, 2024, down from $9.5 million as of June 30, 2024.
- The company is reliant on securing additional funding sources for future operating cash requirements, indicating potential financial constraints.
- Palatin Technologies Inc (PTN) faces uncertainties and risks associated with their forward-looking statements, as highlighted in their SEC filings.
Greetings. Welcome to Palatinâs Second quarter fiscal year 2025 operating results conference call. (Operator Instructions)
Before we begin our remarks, I would like to remind you that statements made by Palatin. Are not historical facts and may be forward-looking statements. These statements are based on assumptions that may or may not prove to be accurate and that the actual results may differ materially from those anticipated due to the variety of risks and uncertainties discussed in the company's most recent filings with the Security and Exchange Commission.
Please consider such risks and uncertainties carefully in evaluating these forward-looking statements by Palatin's prospects. Now I would like to turn the call over to our host, Dr. Carl Spana, President, Chief Executive Officer of Palatin. Please go ahead.
Thank you. Good morning and welcome to the Palatin Second quarter fiscal year 2025 call. I'm Dr. Carl Spana, Chief Executive Officer, and President
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
